

EXPLORING THE MECHANISM BEHIND METABOLIC RISK FACTORS FOR ALZHEIMER DISEASE. AN INTEGRATIVE APPROACH TO TYPIFY DISEASE PATHWAYS, OPTMISE DIAGNOSIS AND TREATMENT.

<https://neurodegenerationresearch.eu/survey/exploring-the-mechanism-behind-metabolic-risk-factors-foralzheimer-disease-an-integrative-approach-to-typify-diseasepathways-optmise-diagnosis-and-treatment/>

Principal Investigators

Angel Cedazo-Minguez

Institution

Karolinska Institute

Contact information of lead PI Country

Sweden

Title of project or programme

EXPLORING THE MECHANISM BEHIND METABOLIC RISK FACTORS FOR ALZHEIMER DISEASE. AN INTEGRATIVE APPROACH TO TYPIFY DISEASE PATHWAYS, OPTMISE DIAGNOSIS AND TREATMENT.

Source of funding information

The Swedish Brain Foundation

Total sum awarded (Euro)

€ 54,407

Start date of award

01/07/2015

Total duration of award in years

1.5

Keywords

Research Abstract

Alzheimer disease (AD) is the major cause of dementia. Because of the worldwide aging phenomenon of the population, AD has increasing public health relevance. AD is characterised for the accumulation in brain of extracellular amyloid β -peptide (A β) and intracellular neurofibrillary tangles formed by abnormally hyper-phosphorylated tau (p-tau). Familial AD represents only about 1% of all AD cases. An increasing consensus points AD as multifactorial and heterogenous. The hypothesis that AD is caused by a metabolic imbalance of brain cells has gained increasing experimental support. Type 2 diabetes (T2D), hypertension and high serum cholesterol at midlife increase the risk for AD. Our project aims to explore the molecular links between AD and metabolic impairments, with focus on cholesterol and glucose metabolisms as well as insulin resistance. Our main objectives are: 1) To explore the contribution of metabolic alterations to AD development/progression; 2) To find new biomarkers for AD variant etiologies or subtypes; and 3) To provide information for helping in the design of AD clinical trials, giving emphasis in the selection of the targeted patient population.

Further information available at:

Types:

Investments < €500k

Member States:

Sweden

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A